Indications |
Oral Hypertension Adult: As conventional tablet or oral solution: Initially, 40-80 mg bid. Usual range: 160-320 mg daily. As extended release tablet: Initially, 80 mg once daily. Usual range: 120-160 mg once daily. Max: 640 mg daily. Child: Initially, 1 mg/kg daily in divided doses, may increase to 2-4 mg/kg daily in 2 divided doses. Oral Phaeochromocytoma Adult: 60 mg daily given on the 3 days before the operation with α-blockade. Prolonged treatment of 30 mg daily may be given if tumour is inoperable. Child: 250-500 mcg/kg 3-4 times daily. Oral Myocardial infarction Adult: 40 mg 4 times daily for 2-3 days followed by 80 mg bid. Alternatively, 180-240 mg daily in divided doses. Doses to be given within 5-21 days of MI. Oral Cardiac arrhythmias Adult: 30-160 mg daily in divided doses. Child: 250-500 mcg/kg 3-4 times daily. Oral Prophylaxis of migraine Adult: Initially, 40 mg bid-tid increased to 160 mg daily. Up to 240 mg daily may be necessary. Discontinue therapy if satisfactory response not obtained within 4-6 wk after reaching max dose. Child: <12 yr: 20 mg bid-tid. Oral Portal hypertension Adult: Initially, 40 mg bid increased up to 160 mg bid. Oral Angina pectoris Adult: As conventional tablet or oral solution: 40 mg bid-tid, may increase to 120-240 mg daily, up to 320 mg daily may be required in some patients. As extended release tablet: 80 mg once daily, increased as needed every 3-7 days, average dose 160 mg once daily, max: 320 mg daily. Oral Hypertrophic cardiomyopathy Adult: 10-40 mg, given 3-4 times daily. Oral Hyperthyroidism Adult: 10-40 mg, given 3-4 times daily. Oral Anxiety Adult: 40 mg once daily, may increase to bid-tid. Oral Essential tremor Adult: 40 mg bid-tid. May increase at wkly intervals to 160 mg daily. Up to 320 mg daily may be necessary. Intravenous Emergency treatment of cardiac arrhythmias Adult: 1 mg injected over a period of 1 minute, repeated every 2 minutes, if needed. Max: 10 mg in conscious patients and 5 mg in patients under anaesthesia. Child: 25-50 mcg/kg via slow inj, may be repeated 3-4 times daily. Intravenous Hyperthyroidism Adult: 1 mg, given over 1 minute, may repeat at 2-minute intervals until response is observed or a max of 10 mg is used in conscious patients or 5 mg in patients who are under anaesthesia. |
Contraindications |
Sinus bradycardia, cardiogenic shock, pulmonary oedema, severe hyperactive airway disease, compensated cardiac failure, Raynaud's disease, hypoglycaemia, severe haemorrhage, metabolic acidosis, severe peripheral arterial disease, 2nd or 3rd degree heart block. Pregnancy (2nd and 3rd trimesters). |
Warnings / Precautions |
Compensated heart failure, peripheral vascular disease, diabetes. Switching from conventional to sustained-release preparations, elderly. Ischaemic heart disease, congestive cardiac failure, renal or hepatic dysfunction. Increased risk of bradycardia and hypotension in patients with underlying cardiac disorders. 1st degree heart block. May mask symptoms of hyperthyroidism and hypoglycaemia. May unmask myasthenia gravis. Abrupt withdrawal may lead to angina, MI, ventricular arrhythmias and death. Lactation. |
Adverse Reactions |
Cold extremities, insomnia, fatigue, dizziness, vivid dreams, lassitude, nausea, constipation or diarrhoea, vomiting, anorexia, stomach discomfort, impotence. Weakness, paraesthesia, wheezing, pharyngitis, bronchospasm. CNS disturbances at higher doses and mood alterations. Thrombocytopenic purpura, agranulocytosis, nonthrombocytopenic purpura, thrombocytopenia. Depression, confusion, cognitive dysfunction, emotional lability, fatigue, hallucinations. Potentially Fatal: Heart failure, heart block and bronchospasm. |
Overdose Reactions |
Severe and occasionally fatal CV depression. |
Drug Interactions |
Decreased effect with aluminum and calcium salts, NSAIDs, ampicillin, rifampicin. Concurrent use with chlorpromazine results in raised blood levels of both drugs and additive hypotensive effect. Hypotensive effect reduced by indometacin. Additive effect with other antihypertensives and diuretics. May reduce the clearance of bupivacaine. Plasma levels may be increased by hydralazine and propafenone. Increased serum levels of thioridazine when used with propranolol. Potentially Fatal: Marked hypertension and bradycardia with adrenaline. Rebound hypertension due to abrupt withdrawal of clonidine is potentiated. Severe bradycardia may occur with digitalis. See Below for More propranolol Drug Interactions |
Lab Interactions |
Metabolite may interfere with bilirubin and metanephrine measurements. |
Mechanism of Actions |
Propranolol competitively blocks β1- and β2-receptors resulting to decreased heart rate myocardial contractility, BP and myocardial oxygen demand. It only possesses membrane-stabilising properties. Absorption: Almost completely absorbed from the GI tract (oral); peak plasma concentrations after 1 hr. Distribution: Crosses the blood-brain barrier and placenta, enters breast milk. Protein-binding: 90%. Metabolism: Hepatic; yields 4-hydroxypropranolol (biologically active). Excretion: Via urine (as metabolites and small amounts of unchanged drug); 3-6 hr (elimination half-life). May be removed by dialysis. |
Administration |
Tab: Should be taken on an empty stomach. (Take before meals.) Cap: May be taken with or without food. (Take consistently either always w/ or always w/o meals.) |
Storage Conditions |
Intravenous: Store at 20-25°C. Oral: Store at 20-25°C. |
ATC Classification |
C07AA05 - propranolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases. |
Storage |
Intravenous: Store at 20-25°C. Oral: Store at 20-25°C. |
Available As |
|
Propranolol
Post Review about Propranolol Click here to cancel reply.
Propranolol Containing Brands
Propranolol is used in following diseases
Drug - Drug Interactions of Propranolol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.